Ambea AB (SE:AMBEA)
:AMBEA
Top Page
Ambea AB
(AMBEA)
Select Model
Select Model
Rating:63Neutral
Price Target:
kr143.00
▲(3.40% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by solid financial performance—especially strong free cash flow and steady revenue growth—partly offset by meaningful leverage risk. Technicals materially reduce the score due to a pronounced downtrend and weak momentum, while valuation is supportive but only moderately attractive.
Positive Factors
Free Cash Flow Strength
Consistent, high free cash flow that tracks net income indicates strong earnings quality and internal funding capacity. Over the medium term this supports reinvestment in facilities, servicing of obligations, and potential debt reduction without depending heavily on external capital, improving resilience to shocks.
Negative Factors
Elevated Leverage
Material leverage at ~2.2–2.4 reduces financial flexibility and raises refinancing and interest‑rate sensitivity. For a service provider with modest margins, high debt amplifies the consequences of any revenue or cost shocks and limits room for strategic investments or margin recovery over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Consistent, high free cash flow that tracks net income indicates strong earnings quality and internal funding capacity. Over the medium term this supports reinvestment in facilities, servicing of obligations, and potential debt reduction without depending heavily on external capital, improving resilience to shocks.
Read all positive factors
Ambea AB (AMBEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr10.14B
Dividend Yield1.56%
Average Volume (3M)135.59K
Price to Earnings (P/E)17.8
Beta (1Y)0.59
Revenue Growth10.83%
EPS Growth16.24%
CountrySE
Employees38,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.76
Shares Outstanding84,101,290
10 Day Avg. Volume127,005
30 Day Avg. Volume135,589
Financial Highlights & Ratios
PEG Ratio1.73
Price to Book (P/B)2.27
Price to Sales (P/S)0.74
P/FCF Ratio5.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.66
Revenue Forecast (FY)kr17.14B
Ambea AB Business Overview & Revenue Model
Company Description
Ambea AB (publ) provides housing, support, education, and personnel for health and social care for the elderly and people with disabilities in Sweden, Norway, and Denmark. The company operates through Nytida, Vardaga, Stendi, Altiden, and Klara se...
How the Company Makes Money
Ambea AB generates revenue primarily through government contracts and funding for its care services. The company receives payments from municipal and regional authorities for the provision of healthcare and social services, which form the bulk of ...
Ambea AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
55
Neutral
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.04B | 14.20B | 13.31B | 12.63B | 11.48B |
| Gross Profit | 2.81B | 2.44B | 3.44B | 12.19B | 11.06B |
| EBITDA | 2.71B | 2.61B | 2.28B | 2.04B | 1.61B |
| Net Income | 665.00M | 620.00M | 455.00M | 366.00M | 237.00M |
Balance Sheet | |||||
| Total Assets | 20.48B | 18.48B | 17.89B | 17.88B | 16.67B |
| Cash, Cash Equivalents and Short-Term Investments | 133.00M | 28.00M | 6.00M | 259.00M | 86.00M |
| Total Debt | 12.64B | 11.05B | 10.74B | 10.96B | 9.89B |
| Total Liabilities | 15.28B | 13.49B | 12.97B | 13.19B | 12.14B |
| Stockholders Equity | 5.20B | 4.99B | 4.92B | 4.68B | 4.53B |
Cash Flow | |||||
| Free Cash Flow | 2.03B | 1.95B | 1.62B | 1.33B | 1.11B |
| Operating Cash Flow | 2.17B | 2.07B | 1.71B | 1.44B | 1.21B |
| Investing Cash Flow | -1.39B | -358.00M | -93.00M | -214.00M | -258.00M |
| Financing Cash Flow | -672.00M | -1.69B | -1.88B | -1.04B | -882.00M |
Ambea AB Technical Analysis
Negative
138.30
Price Trends
131.06
Negative
132.26
Negative
127.58
Positive
Market Momentum
0.54
Positive
47.06
Neutral
29.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AMBEA, the sentiment is Negative. The current price of 138.3 is above the 20-day moving average (MA) of 130.98, above the 50-day MA of 131.06, and above the 200-day MA of 127.58, indicating a neutral trend. The MACD of 0.54 indicates Positive momentum. The RSI at 47.06 is Neutral, neither overbought nor oversold. The STOCH value of 29.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:AMBEA.
Ambea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr14.94B | 11.62 | ― | 1.47% | 2.96% | 73.50% | |
64 Neutral | kr9.18B | 12.30 | 12.65% | 2.31% | 9.02% | 29.93% | |
63 Neutral | kr10.14B | 17.78 | 12.96% | 1.56% | 10.83% | 16.24% | |
52 Neutral | kr2.31B | 10.62 | 7.53% | 2.01% | 2.11% | 92.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:AMBEA
Ambea AB
127.80
16.51
14.83%
SE:ATT
Attendo AB
98.30
38.86
65.37%
SE:HUM
Humana AB
43.85
1.96
4.69%
SE:ACAD
AcadeMedia AB
95.40
15.27
19.06%
Ambea AB Corporate Events
Ambea boosts growth and dividend as Nordic care expansion accelerates
Feb 12, 2026
Care group Ambea reported a strong 2025 with net sales up 13% to SEK 16.0 billion, driven by 4% organic and 10% acquired growth, while maintaining an adjusted EBITA margin of 9.6% and lifting earnings per share by 10%. The board proposed raising t...
Ambea Launches Share Buyback to Optimise Capital Structure
Feb 11, 2026
Ambea AB’s board has approved a new share repurchase programme of up to 2,000,000 shares on Nasdaq Stockholm, to be executed by a mandated credit institution ahead of the 2026 annual general meeting. The initiative is designed to optimise th...
Ambea Sets Date for Publication of 2025 Year-End Report and Investor Call
Jan 29, 2026
Ambea has announced that it will publish its year-end report for 2025 on 12 February at 07:00 CET, followed by an English-language webcast and telephone conference at 10:00 CET hosted by CEO Mark Jensen and CFO Benno Eliasson. The scheduled presen...
Ambea Expands Finnish Child and Youth Care Through Acquisition of Sauma
Dec 19, 2025
Ambea, through its Finnish unit Validia, has agreed to acquire Terveystalo Sauma Lastensuojelupalvelut Oy, a Finnish provider of child protection and family care services. Sauma operates 13 residential care units for children and young people acro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.